BlossomHill Therapeutics advances pan-KRAS inhibitor BH-501284 toward Q1 2027 IND filing after preclinical data presentation

• BlossomHill Therapeutics presented preclinical data on BH-501284 at the AACR pancreatic cancer conference held Sept. 25-28, 2026.
• Data supported sustained KRAS pathway suppression with deep, durable tumor responses across several KRAS-mutant cancer models.
• Program positioned for continued development toward an IND submission targeted for Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blossomhill Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280700PRIMZONEFULLFEED9834655) on September 28, 2026, and is solely responsible for the information contained therein.